Oncodesign Precision Medicine obtains Deep TechDevelopment funding for its ANIMUS program

Oncodesign Precision Medicine obtains Deep Tech Development funding for its ANIMUS program

Dijon (France), February 29, 2024, at 6:00pm CET– Oncodesign Precision Medicine (OPM) (ISIN:FR001400CM63 ; Mnemonic : ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announces today that it has received notification of the allocation of financial support from the Deep Tech Development Fund.